SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001564590-18-008002
Filing Date
2018-04-11
Accepted
2018-04-11 16:08:58
Documents
5
Effectiveness Date
2018-04-11

Document Format Files

Seq Description Document Type Size
1 DEFA14A aimt-defa14a_20180523.htm DEFA14A 37922
2 GRAPHIC g201804102152456419077.jpg GRAPHIC 33616
3 GRAPHIC g201804102152457009080.jpg GRAPHIC 6325
4 GRAPHIC g201804102152456899079.jpg GRAPHIC 19592
5 GRAPHIC g201804102152456569078.jpg GRAPHIC 52366
  Complete submission text file 0001564590-18-008002.txt   193758
Mailing Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884
Business Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884 (650) 614-5220
Aimmune Therapeutics, Inc. (Filer) CIK: 0001631650 (see all company filings)

IRS No.: 452748244 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37519 | Film No.: 18750145
SIC: 2834 Pharmaceutical Preparations